# RBx11160 Phase II Dose Ranging Study RBx/MMV05-06

> **NCT00362050** · PHASE2 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 255 (—)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** Treatment with 3 dose groups of RBx11160 over 7 days

## Key facts

- **NCT ID:** NCT00362050
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 255 (—)
- **Last updated:** 2007-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362050, "RBx11160 Phase II Dose Ranging Study RBx/MMV05-06". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00362050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*